Evidence map›Paper›PMID 33385444›Full record

ArticleThe Journal of allergy and clinical immunology2021

COPD-associated miR-145-5p is downregulated in early-decline FEV

Anshul Tiwari, Jiang Li, Alvin T Kho, Maoyun Sun, Quan Lu, Scott T Weiss, Kelan G Tantisira, Michael J McGeachie

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06385236 (Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06385236 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

TypeinterventionalSponsorUniversity of California, San DiegoRan2024 to 2028Enrolled120ConditionsModerate to Severe AsthmaArmsDupilumab, Benralizumab
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Noncoding RNAs in asthmatic airway smooth muscle cells.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Recent miRNA Research in Asthma.Current allergy and asthma reports · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Anshul TiwariChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.
Jiang LiChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.
Alvin T KhoChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass; Computational Health Informatics Program, Boston Children's Hospital, Boston, Mass.
Maoyun SunMolecular and Integrative Physiological Sciences, Harvard T.H. Chan School of Public Health, Boston, Mass.
Quan LuMolecular and Integrative Physiological Sciences, Harvard T.H. Chan School of Public Health, Boston, Mass.
Scott T WeissChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.
Kelan G TantisiraChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.
Michael J McGeachieChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass. Electronic address: remmg@channing.harvard.edu.
Harvard University · USBrigham and Women's Hospital · US

Funding

Systems Biology of Airway DiseaseP01HL132825 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI WEISS, SCOTT T · 2016 to 2020
$12.6M
Integrative Metabolomics of Asthma SeverityR01HL123915 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LASKY-SU, JESSICA A · 2014 to 2023
$7.0M
Asthma Exacerbations and MicroRNA prediction: Treatment Response in an Underserved Ethnicity (AEM-TRUE)R01HL139634 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MCGEACHIE, MICHAEL JOHN · 2018 to 2022
$4.3M
Omic Determinants of Longitudinal Lung Function in AsthmaR01HL155742 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LASKY-SU, JESSICA A, MCGEACHIE, MICHAEL JOHN · 2021 to 2025
$3.9M
MICRORNAS IN CIRCULATION: ONTOLOGIES OF ASTHMA SEVERITY AND TREATMENT (MICROCOAST)R01HL127332 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G · 2015 to 2018
$3.4M
DISEASE AND HEALTH: ASTHMA RESILIENCE THROUGH MICRORNA ATTRIBUTES (DHARMA)R01HL129935 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G · 2015 to 2017
$1.4M
NHLBI NIH HHS P01 HL132825NHLBI NIH HHS R01 HL123915NHLBI NIH HHS R01 HL127332NHLBI NIH HHS R01 HL129935NHLBI NIH HHS R01 HL139634NHLBI NIH HHS R01 HL155742
6 · The paper itself

Abstract

backgroundMany microRNAs (miRNAs) have been associated with asthma and chronic obstructive pulmonary disease (COPD). Longitudinal lung function growth trajectories of children with asthma-normal growth, reduced growth (RG), early decline (ED), and RG with an ED (RGED)-have been observed, with RG and RGED associated with adverse outcomes, including COPD.

objectiveOur aim was to determine whether circulating miRNAs from an early age in children with asthma would be prognostic of reduced lung function growth patterns over the next 16 years.

methodsWe performed small RNA sequencing on sera from 492 children aged 5 to 12 years with mild-to-moderate asthma from the CAMP clinical trial, who were subsequently followed for 12 to 16 years. miRNAs were assessed for differential expression between previously assigned lung function growth patterns.

resultsWe had 448 samples and 259 miRNAs for differential analysis. In a comparison of the normal and the most severe group (ie, normal growth compared with RGED), we found 1 strongly dysregulated miRNA, hsa-miR-145-5p (P < 8.01E-05). This miR was downregulated in both ED groups (ie, ED and RGED). We verified that miR-145-5p was strongly associated with airway smooth muscle cell growth in vitro.

conclusionOur results showed that miR-145-5p is associated with the ED patterns of lung function growth leading to COPD in children with asthma and additionally increases airway smooth muscle cell proliferation. This represents a significant extension of our understanding of the role of miR-145-5p in COPD and suggests that reduced expression of miR-145-5p is a risk factor for ED of long-term lung function.

Indexed as

Gene Expression RegulationChildChild, PreschoolDown-RegulationForced Expiratory VolumeGene Expression ProfilingHumansMicroRNAsPulmonary Disease, Chronic ObstructiveRespiratory Function TestsRNA InterferenceRNA, MessengerSeverity of Illness IndexMicroRNAsMIRN145 microRNA, humanRNA, Messengerairway smooth muscleAsthmaChildhood Asthma Management ProgramCOPDlung growth patternsmiRNA

Identifiers

PMID33385444
PMCPMC8184594
OpenAlexW3117110291

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.